Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Writing · Drug excipient

Drug Excipients: Definition, Functional Categories and the Limits of the Term “Inactive”

An excipient is any component of a dosage form other than the active substance, and very few excipients are inert. Excipients determine disintegration, stability, bioavailability and, in some populations, toxicity. A formulation section that names excipients without grade, function and source is not reproducible, and reviewers increasingly identify this deficiency.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time12 minutes Sources26 peer-reviewed

The term “excipient” is commonly understood as the opposite of “active”, which is a useful first approximation but an inadequate working definition. Excipients carry functional roles that are specified, tested and sometimes compendially controlled; they interact chemically with the active substance; they vary between suppliers and between lots of the same supplier; and a few have documented dose-limiting toxicity in neonates and children. For authors of a formulation or materials section, the relevant question is not what excipients are but what must be reported about those used.

Learning objectives

  • A working definition of excipient that holds at the boundaries — counter-ions, container closure components, processing aids
  • The functional categories from which a formulation is built, and which functions compete with each other
  • Why “inactive ingredient” is a regulatory label rather than a pharmacological claim
  • How to read the FDA Inactive Ingredient Database and what its numbers do and do not license
  • What a reviewer expects a formulation or materials paragraph to state about every excipient — grade, function, source, specification
  • Where excipient interaction and lot-to-lot variability sit in a stability or material selection argument

Common misconceptions

  • “Inactive means pharmacologically inert.” The term means that the ingredient is not intended to exert a therapeutic effect. Belayneh and colleagues, in the International Journal of General Medicine, document benzyl alcohol exposure as low as 130 mg/kg per day linked to fatal gasping syndrome in premature neonates.
  • “If it is in a marketed product, it is safe at any level in mine.” The FDA’s Inactive Ingredient Database records maximum potency per unit dose by route and dosage form. It is a precedent record, not a blanket safety limit, and it provides no information about a particular patient population.
  • “Excipients are interchangeable if the chemical name matches.” Dave and colleagues, in the Journal of Pharmaceutical Sciences, show that lot-to-lot and supplier-to-supplier variability in the same named excipient changes dosage-form functionality.
  • “Excipients do not react with the drug.” Bharate and colleagues catalogue API–excipient incompatibilities across functional classes in the Journal of Excipients and Food Chemicals; Narang and colleagues treat excipient interaction as a primary determinant of solid dosage form stability.
  • “Naming the excipient is enough for the methods section.” A name without grade, viscosity or substitution type, function and supplier does not allow the formulation to be reproduced.

Definition of an excipient

The usable definition is negative and deliberately broad: an excipient is any substance other than the active pharmaceutical ingredient that is included in a finished dosage form, or used in its manufacture, and that is intended to perform a function. The function is the operative part. A diluent converts a 2 mg dose into a tablet that can be handled; a disintegrant causes that tablet to break apart; a chelating agent prevents a trace metal from catalysing oxidation. None of these is therapeutic, yet each performs a function.

Three boundaries cause most of the confusion. The first is the counter-ion of a salt. Apte, writing in the International Journal of Pharmaceutical Excipients, argues that the counter-ion should be treated as a functional excipient, because it changes solubility, hygroscopicity and crystal habit while travelling as part of the drug substance name 21. In regulatory terms the besylate in amlodipine besylate is part of the active pharmaceutical ingredient; in formulation terms it behaves like an excipient that cannot be changed independently. Authors should state which convention they adopt.

The second is the container closure system. The FDA treats container closure components under their own guidance rather than as excipients, and its draft guidance on container closure systems for human drugs and biological products sets out the leachables, extractables and compatibility expectations separately 1. A rubber stopper is not an excipient, but it can alter a formulation as effectively as one.

The third is processing aids — solvents removed during manufacture, lubricants applied to tooling. These are not components of the finished product but they are part of the formulation record, and residual solvent limits apply to them.

Functional categories of excipients and their competing functions

Formulations are assembled by function, not by chemistry, and they are usefully conceived as a short list of functions. Milic and colleagues, in Arhiv za farmaciju, set out why functionality rather than identity is the compendially meaningful property: two grades of the same named polymer can occupy different functional categories, and the pharmacopoeial move towards functionality-related characteristics follows from that 19.

The categories are not independent. Increasing a binder to improve tablet hardness slows disintegration. A superdisintegrant that gives fast dispersion raises hygroscopicity and can shorten shelf life. A surfactant added to improve wetting of a poorly soluble drug may also increase degradation by dissolving a reactive impurity into the aqueous phase. A transparent formulation rationale names the trade-off it accepted, which is also what ICH Q8(R2) asks for when it describes the link between material attributes, process parameters and the quality target product profile 4,9.

Functional categories from which a solid oral formulation is built

FunctionIntended functionWhat it trades against
Diluent / fillerMake a small dose into a handleable unit of reproducible weightDilution of the drug load; compaction behaviour; moisture contribution
BinderHold the granule or compact together through handlingHigher binder level slows disintegration and dissolution
DisintegrantBreak the compact apart on contact with fluidSuperdisintegrants are hygroscopic; faster dispersion can cost shelf life
Lubricant / glidantPrevent sticking to tooling; improve powder flowHydrophobic lubricants retard wetting and can reduce tablet strength
Surfactant / solubiliserWet and solubilise a poorly soluble drugMay mobilise reactive species and alter degradation pathways
Stabiliser (antioxidant, chelator, buffer)Suppress a specific degradation routeBuffer species set microenvironmental pH, which can accelerate a different route
PreservativeControl microbial growth in multi-dose and aqueous productsSeveral carry documented age-dependent safety concerns
Coating, colourant, flavourModify release, mask taste, aid identification and adherenceAdded process steps; colourant and sweetener sensitivities in children

Categories as framed in the excipient functionality literature — Milic and colleagues on compendial functionality in Arhiv za farmaciju, Narang and colleagues on excipient interaction and solid dosage form stability, and Jain and colleagues on co-processed excipients in Polymers in Medicine. The trade-off column is the design tension each function creates, not a quantified effect.

“Inactive” as a regulatory rather than a pharmacological designation

The phrase “inactive ingredient” means not intended to exert a therapeutic effect in the product as formulated. It does not mean biologically inert, and the paediatric literature shows where this becomes clinically serious. Belayneh and colleagues, in the International Journal of General Medicine, report that about 60% of paediatric formulations are prescribed off-label, which means children routinely receive excipient exposures that were never evaluated in children 17. The same review records benzyl alcohol exposure as low as 130 mg/kg per day linked to fatal gasping syndrome in premature neonates, and notes that Kaletra oral solution contains 42.4% ethanol by volume as an excipient 17.

Rouaz El Hajoui and colleagues, in Pharmaceutics, reach the same conclusion from the formulation side: several widely used preservatives, solvents, sweeteners and colourants carry age-dependent concerns that adult safety data do not resolve 12. Comoglu and Ozyilmaz, in Pharmaceutical Development and Technology, extend the argument to geriatric formulations, where swallowing ability, polypharmacy and renal handling change what an acceptable excipient load looks like 6.

The practical consequence for a manuscript is straightforward. Where the study population includes neonates, children or frail older adults, the excipient list is clinical information and belongs in the paper, not only in a supplementary materials table.

60%of paediatric formulations prescribed off-label
130 mg/kg/daybenzyl alcohol linked to fatal gasping syndrome in premature neonates
42.4% v/vethanol present as an excipient in Kaletra oral solution

Figures as reported in Belayneh A, Tadese E, Molla F. Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations. International Journal of General Medicine. 2020;13:1051-1066.

Regulatory status and interpretation of the Inactive Ingredient Database

Excipients are not approved in their own right in the United States. They acquire acceptability through use in an approved product, through a compendial monograph in USP–NF or another recognised pharmacopoeia, or through data submitted with the application that uses them. The practical register of precedent is the FDA’s Inactive Ingredient Database, which lists ingredients by route of administration and dosage form with a maximum potency observed in approved products 3.

Two aspects of the IID are routinely misread. The first is what the maximum potency figure licenses: it is the highest level the agency has seen in an approved product for that route and dosage form, not a safety threshold, and not a guarantee of acceptability in a different product or population 3. The second is that the database has been actively restructured. In its questions and answers on IID enhancements, the FDA explained that standardising routes of administration and dosage forms was expected to reduce the number of database entries from more than 14,000 to about 10,000 — consolidation of duplicate and inconsistently coded records, not removal of ingredients 3. The agency’s CDER Office of Generic Drugs has since presented further IID programme work, including how artificial intelligence might be applied to the database, at its FY2026 generic drug science and research workshop 2.

Where the IID is cited in a manuscript, it should be cited as a precedent record with a retrieval date, and the route and dosage form matched should be stated. A citation without those two qualifiers is not checkable. The ICH guideline set covers the parallel expectations for impurities and residual solvents that excipients contribute to.

Excipient interaction and variability as determinants of stability

Excipient–API interaction is the better documented of the two. Bharate and colleagues, in the Journal of Excipients and Food Chemicals, give a comprehensive account organised by functional class — Maillard reactions between amine drugs and reducing sugars, acid-catalysed hydrolysis driven by excipient microenvironmental pH, oxidation promoted by peroxide residues in polymeric excipients 20. Narang and colleagues treat the same phenomena as a primary determinant of solid dosage form stability rather than an edge case 24. Awasthi and Banerjee, in RSC Pharmaceutics, illustrate the current direction of research: combined in silico and in vitro screening of excipient compatibility for atenolol and amlodipine besylate, used to steer solid oral dosage form design before a formulation is made 5.

Variability is the less conspicuous problem. Dave and colleagues, in the Journal of Pharmaceutical Sciences, document how functionality of the same named excipient shifts between lots and suppliers, with measurable consequences for compaction, flow and dissolution 23. This is why a formulation section needs supplier and lot information: a reader who cannot identify the material cannot distinguish a genuine formulation effect from a lot effect.

Solid-state behaviour of the active substance interacts with both. Saifee and colleagues review drug polymorphism in the International Journal of Health Research, and Lu and Rohani, in Current Medicinal Chemistry, review polymorphism and crystallisation of APIs as determinants of solubility, stability and bioavailability 25,26. An excipient that alters microenvironmental water activity can alter which polymorph persists.

Co-processed and multifunctional excipients

Co-processed excipients are physical combinations of two or more established excipients, processed together to obtain functionality that neither gives alone, without a new chemical entity being formed 18. Jain and colleagues, in Polymers in Medicine, review their use in fast-disintegrating tablets, where the functional target is defined by the dosage form: orodispersible tablets are required to disperse in under 3 min in the buccal cavity before swallowing, and achieving that while keeping adequate mechanical strength is precisely the trade-off that a single-function excipient handles poorly.

Liew and colleagues have reviewed the field twice — in the International Journal of Pharmacy and Pharmaceutical Sciences and in the Journal of Pharmaceutical Negative Results — and both reviews acknowledge that the regulatory position lags behind the technology 10,18. A co-processed excipient made from compendial components does not automatically inherit a compendial monograph, and the absence of one is a real obstacle rather than a formality. Authors should state which applies: a named commercial co-processed grade, or a combination prepared by the authors, in which case the preparation forms part of the methods.

Required content of a formulation or materials section

The characteristic failure in materials paragraphs is to name compounds as if the name were a specification. “Microcrystalline cellulose” covers grades that differ in particle size, moisture and compactibility; “hydroxypropyl methylcellulose” covers substitution types and viscosity grades that behave as different materials. For every excipient, a reader needs four things: the identity and grade, the function it was included for, the source with lot where functionality matters, and the compendial or in-house specification it met.

Quantity matters too, and should be given as percentage of the total formulation as well as absolute amount per unit, because the percentage is what transfers to a different batch size. Where precedent was relied on for an unusual level, its source should be stated. The before-and-after below is the same formulation reported two ways.

The same formulation, reported two ways

Not reproducible

Tablets were prepared by direct compression using microcrystalline cellulose, lactose, croscarmellose sodium and magnesium stearate. All excipients were of pharmaceutical grade and obtained from commercial suppliers. Tablets were evaluated for hardness, friability and disintegration.

Which grade of microcrystalline cellulose? Grades differ in particle size, moisture and compactibility, so the formulation cannot be reproduced.

What was each excipient for? Function is left to be inferred, which hides the design rationale.

How much of each? No quantities, so neither the drug load nor the disintegrant level can be judged.

Which specification was met? “Pharmaceutical grade” is not a specification, and “commercial suppliers” is not a source.

Was lubricant blending controlled? Over-blending magnesium stearate is a classical cause of strength loss and is not addressed.

Reproducible

Tablets (200 mg nominal weight) were prepared by direct compression. Each tablet contained 10 mg atenolol (USP, lot ATE-2214), microcrystalline cellulose NF grade Avicel PH-102 (102 mg, 51.0% w/w; lot MCC-8831) as diluent, spray-dried lactose monohydrate NF (70 mg, 35.0% w/w) as co-diluent, croscarmellose sodium NF (14 mg, 7.0% w/w) as disintegrant, colloidal silicon dioxide NF (2 mg, 1.0% w/w) as glidant and magnesium stearate NF, vegetable source (2 mg, 1.0% w/w) as lubricant. Suppliers and lot numbers for all components are given in Supplementary Table S1. Each excipient met its current USP-NF monograph, including the functionality-related characteristics where the monograph lists them; magnesium stearate was blended for a fixed 3 min at 25 rpm because longer blending reduced tablet tensile strength in pilot runs.

Grade and trade designation make the material identifiable, and the lot lets a reader distinguish a formulation effect from a lot effect — the variability Dave and colleagues document.

Each component carries its function, so the rationale and the trade-offs are visible.

Quantities are given per unit and as percentage w/w, so the formulation transfers to another batch size.

The compendial reference is named, including functionality-related characteristics, which is the compendially meaningful property rather than identity alone.

A process parameter that materially changed the outcome is stated with the observation that drove it.

The second version is approximately four lines longer and removes five separate grounds on which a reviewer could judge the formulation unreproducible. It contains no literature claims; all of it is information the authors already held in their batch record but did not transfer to the manuscript.

Unresolved questions

Three gaps should be stated explicitly rather than circumvented. First, there is no consolidated, population-specific safe exposure limit set for most excipients in neonates and young children; Belayneh and colleagues and Rouaz El Hajoui and colleagues both describe the evidence as fragmentary, drawn from case reports and extrapolation rather than from paediatric exposure studies 12,17. Second, the regulatory route for genuinely novel excipients remains the main constraint on excipient innovation, and the co-processed excipient reviews describe the position as unresolved rather than as solved differently in different regions. Third, excipient functionality prediction is improving but not sufficiently reliable to replace compatibility testing; Awasthi and Banerjee position their in silico work as a screen that narrows experiments, not one that removes them.

Where biologics are concerned, the excipient question changes fundamentally. Jiskoot and colleagues, in the Journal of Pharmaceutical Sciences, and Hu and colleagues, in the AAPS series, describe high-concentration monoclonal antibody formulation as a problem dominated by viscosity, aggregation and surfactant choice rather than by disintegration and compaction; Estapé Senti and colleagues, in Advanced Drug Delivery Reviews, describe lipid nanoparticle components for mRNA delivery, where the “excipient” is the delivery system and arguably part of the active principle 7,13,15. Our page on bio-macromolecules takes that distinction further, and the wider concepts and definitions hub places excipients alongside the device-side equivalent, material selection for medical devices.

Key points

Key points

An excipient is any non-active component included to perform a function, and the functions are real: disintegration, stabilisation, solubilisation, taste masking. “Inactive” is a statement of therapeutic intent, not of biological inertness, and in neonates and children specific excipients have documented dose-dependent harm. Regulatory acceptability comes from precedent and compendial status rather than standalone approval, so the Inactive Ingredient Database should be cited as a precedent record, matched on route and dosage form, with a retrieval date. For reporting, the standard comprises four items per excipient: identity and grade, function, source with lot, and specification met.

Application to your study

Application to your study

  1. Every component should be listed, including those that may appear not to count. Counter-ion, residual processing solvent and coating sub-components should be included. Authors should decide and state whether the counter-ion is treated as part of the drug substance or as a functional excipient.
  2. Each excipient should be assigned a function in the manuscript, not merely a name. If the purpose of a component cannot be stated, the formulation rationale is incomplete.
  3. Each reference to “pharmaceutical grade” should be replaced with the actual grade. The viscosity grade, substitution type, particle-size grade or trade designation should be given where that is what identifies the material.
  4. Supplier and lot should be reported for any excipient whose functionality drives the result. This information allows readers to distinguish the reported effect from lot-to-lot variability.
  5. Amounts should be stated both per unit and as percentage w/w. The percentage is the value that transfers to a different batch size.
  6. Excipient levels should be checked against the IID for the matching route and dosage form. The retrieval date should be recorded, since the database is actively restructured and entries have been consolidated.
  7. Where the study population includes children or frail older adults, the excipient list should be treated as clinical data. The list should be reported in the paper, with ethanol, benzyl alcohol, propylene glycol and preservative content named explicitly and the implied exposure per dose stated.
  8. Compatibility work should be reported, including work that was not performed. A binary mixture study at accelerated conditions merits reporting even when no interaction was observed; omission is interpreted as absence.

Frequently asked questions

The active pharmaceutical ingredient is the component intended to exert the therapeutic effect; an excipient is any other component included to perform a function in the dosage form or its manufacture. The distinction is one of intent rather than of activity, which is why “inactive ingredient” is a misleading synonym. The boundary is blurred in two notable places: the counter-ion of a salt travels as part of the drug substance but behaves functionally like an excipient, as Apte argues in the International Journal of Pharmaceutical Excipients; and in lipid nanoparticle products the delivery components are arguably part of the active principle. Our API definition page works the other side of the same line.

Not in their own right in the United States. An excipient becomes acceptable through use at a given level in an approved drug product for a given route and dosage form, through a monograph in USP–NF or another recognised pharmacopoeia, or through data submitted in the application that uses it. The practical consequence is that no list of “approved excipients” exists from which to work. There is a precedent record — the Inactive Ingredient Database — and a compendial route. A genuinely novel excipient has no precedent, which is the main reason excipient innovation is slow.

It should be cited as a precedent record, with the route of administration and dosage form matched and the retrieval date stated. The maximum potency figure is the highest level the agency has observed in an approved product for that route and dosage form — not a safety limit, and not transferable to another route. The retrieval date matters because the database is actively maintained: in its questions and answers on IID enhancements, the FDA explained that standardising routes and dosage forms was expected to reduce entries from more than 14,000 to about 10,000 through consolidation of duplicated and inconsistently coded records.

The recurring concerns are ethanol, benzyl alcohol, propylene glycol, parabens and benzoates, and certain colourants and sweeteners. Belayneh and colleagues, in the International Journal of General Medicine, report benzyl alcohol exposure as low as 130 mg/kg per day linked to fatal gasping syndrome in premature neonates, and note that Kaletra oral solution contains 42.4% ethanol by volume. They also report that about 60% of paediatric formulations are prescribed off-label, so these exposures occur in children for whom the product was never evaluated. Rouaz El Hajoui and colleagues reach the same conclusions in Pharmaceutics. The accurate position is that population-specific limits for most excipients in neonates do not exist.

They should be reported wherever excipient functionality could plausibly influence the result, which for solid dosage forms is almost always the case. Dave and colleagues, in the Journal of Pharmaceutical Sciences, show that the same named excipient varies in functionality between lots and between suppliers enough to change compaction, flow and dissolution behaviour. Without supplier and lot, a reader cannot tell whether the finding is a formulation effect or a material effect, and a failed replication cannot be diagnosed. Where the list is long, identity, grade, function and quantity should be given in the main text and the supplier and lot table in supplementary material.

A co-processed excipient is two or more established excipients processed together — typically co-spray-dried or co-granulated — to obtain functionality that neither provides alone, with no new chemical entity formed. Jain and colleagues review their use for fast-disintegrating tablets in Polymers in Medicine, where orodispersible tablets must disperse in under 3 min in the buccal cavity. Regarding monographs, the position is unresolved: being made from compendial components does not confer a compendial monograph on the combination, and Liew and colleagues describe the regulatory pathway as the field’s main obstacle rather than a settled matter.

Authors should report the work performed and the work deliberately not performed. The usual minimum is binary drug–excipient mixtures held at accelerated temperature and humidity, assayed for drug content and for new degradation peaks, with a named analytical method and a stated limit of detection. Bharate and colleagues, in the Journal of Excipients and Food Chemicals, set out the interaction chemistries worth looking for by functional class, and Awasthi and Banerjee, in RSC Pharmaceutics, demonstrate in silico pre-screening as a way of narrowing which pairs to test. Negative results are informative in this context and should be reported rather than omitted.

Both, and the bioavailability route is the one more often underreported. Surfactants and solubilisers change wetting and apparent solubility; hydrophobic lubricants retard dissolution; polymeric excipients can inhibit crystallisation and keep an amorphous drug in a higher-energy, better-dissolving state. Excipients also interact with the solid-state behaviour of the drug: Lu and Rohani, in Current Medicinal Chemistry, and Saifee and colleagues, in the International Journal of Health Research, review polymorphism and crystallisation as determinants of solubility, stability and bioavailability, and an excipient that changes local water activity can change which form persists on storage.

References

  1. U.S. Food and Drug Administration. Container Closure Systems for Human Drugs and Biological Products (draft guidance). U.S. Food and Drug Administration. 2026. read 9 October 2026. packagingdigest.com
  2. U.S. Food and Drug Administration, CDER Office of Generic Drugs. FDA's Inactive Ingredient Database (IID) Program & AI Consideration. FDA FY2026 Generic Drug Science and Research Initiatives Public Workshop. 2026. read 9 October 2026. fda.gov
  3. U.S. Food and Drug Administration. Questions and Answers Regarding Enhancements to the Inactive Ingredient Database (IID). U.S. Food and Drug Administration (CDER). 2019. read 9 October 2026. fda.gov
  4. International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
  5. Awasthi G, Banerjee S. Merged in silico-in vitro validations of atenolol and amlodipine besylate with excipient interactions for the design of solid oral dosage forms. RSC Pharmaceutics. 2026. doi:10.1039/D6PM00014B read 9 October 2026. doi.org/10.1039/D6PM00014B
  6. Comoglu T, Ozyilmaz ED. Pharmaceutical excipients in pediatric and geriatric drug formulations: safety, efficacy, and regulatory perspectives. Pharmaceutical Development and Technology. 2025;30(1):1-9. doi:10.1080/10837450.2024.2441181 read 9 October 2026. doi.org/10.1080/10837450.2024.2441181
  7. Estape Senti M, Garcia Del Valle L, Schiffelers RM. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond. Advanced Drug Delivery Reviews. 2024;206:1-17. doi:10.1016/j.addr.2024.115190 read 9 October 2026. doi.org/10.1016/j.addr.2024.115190
  8. Jain S, Kaur S, Rathi R, Nagaich U, Singh I. Application of co-processed excipients for developing fast disintegrating tablets: A review. Polymers in Medicine. 2023;53(1):59-68. doi:10.17219/pim/158009 read 9 October 2026. doi.org/10.17219/pim/158009
  9. Comoglu T, Ozyilmaz ED. Pharmaceutical product development: a "quality by design" (QbD) approach. 2023;1:285-310. doi:10.1016/B978-0-323-91817-6.00001-2 read 9 October 2026. doi.org/10.1016/B978-0-323-91817-6.00001-2
  10. Liew KB, Hii SH, Helal Uddin ABM, Sarker ZI, Chew YL. Co-processed excipients: a revisit of its development in the past two decades; a review. Journal of Pharmaceutical Negative Results. 2022;13(7):96-103. read 9 October 2026. irep.iium.edu.my
  11. Zheng X, Zhang P, Fu Z, Meng S, Dai L, Yang H. Applications of nanomaterials in tissue engineering. RSC Advances. 2021;11:19041-19058. doi:10.1039/d1ra01849c read 9 October 2026. doi.org/10.1039/d1ra01849c
  12. Rouaz El Hajoui K, Chiclana Rodriguez B, Nardi Ricart A, et al. Excipients in the Paediatric Population: A Review. Pharmaceutics. 2021;13(3):387. doi:10.3390/pharmaceutics13030387 read 9 October 2026. doi.org/10.3390/pharmaceutics13030387
  13. Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis? Journal of Pharmaceutical Sciences. 2021;111(4):861-867. doi:10.1016/j.xphs.2021.11.008 read 9 October 2026. doi.org/10.1016/j.xphs.2021.11.008
  14. Kumar SSD, Abrahamse H. Advancement of nanobiomaterials to deliver natural compounds for tissue engineering applications. International Journal of Molecular Sciences. 2020;21(18):1-27. doi:10.3390/ijms21186752 read 9 October 2026. doi.org/10.3390/ijms21186752
  15. Hu Q, Jiang B, Liu D, Tang X, Daly T, Shameem M. Chapter 14: Practical Considerations in High Concentration Formulation Development for Monoclonal Antibody Drug Products. AAPS Advances in the Pharmaceutical Sciences Series. 2020;35:343-372. doi:10.1007/978-3-030-31415-6_14 read 9 October 2026. doi.org/10.1007/978-3-030-31415-6_14
  16. Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166 read 9 October 2026. doi.org/10.1001/jama.2020.1166
  17. Belayneh A, Tadese E, Molla F. Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations. International Journal of General Medicine. 2020;13:1051-1066. doi:10.2147/IJGM.S280330 read 9 October 2026. doi.org/10.2147/IJGM.S280330
  18. Liew KB, Gaurav A, Mandal UK. A REVIEW ON CO-PROCESSED EXCIPIENTS: CURRENT AND FUTURE TREND OF EXCIPIENT TECHNOLOGY. International Journal of Pharmacy and Pharmaceutical Sciences. 2019;11(1):1-9. doi:10.22159/ijpps.2019v11i1.29265 read 9 October 2026. doi.org/10.22159/ijpps.2019v11i1.29265
  19. Milic J, Calija B, Krajisnik D. Excipients functionality: Importance and compendial status. Arhiv za farmaciju. 2016;66(2):71-90. doi:10.5937/arhfarm1602071M read 9 October 2026. doi.org/10.5937/arhfarm1602071M
  20. Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. Journal of Excipients and Food Chemicals. 2016;1(3). read 9 October 2026. doaj.org
  21. Apte S. The counter ion: expanding excipient functionality. International Journal of Pharmaceutical Excipients. 2016;2(2). doi:10.66617/001c.1126 read 9 October 2026. doi.org/10.66617/001c.1126
  22. Carli Lorenzini G, Olsson A. DESIGN TOWARDS BETTER LIFE EXPERIENCE: CLOSING THE GAP BETWEEN PHARMACEUTICAL PACKAGING DESIGN AND ELDERLY PEOPLE. DS 80-9 Proceedings of the 20th International Conference on Engineering Design (ICED 15). 2015;9:065-076. read 9 October 2026. designsociety.org
  23. Dave VS, Saoji SD, Raut NA, Haware RV. Excipient Variability and Its Impact on Dosage Form Functionality. Journal of Pharmaceutical Sciences. 2015;104(3):906-915. doi:10.1002/jps.24299 read 9 October 2026. doi.org/10.1002/jps.24299
  24. Narang AS, Desai D, Badawy S. Impact of Excipient Interactions on Solid Dosage Form Stability. Excipient Applications in Formulation Design and Drug Delivery. 2015:93-137. doi:10.1007/978-3-319-20206-8_5 read 9 October 2026. doi.org/10.1007/978-3-319-20206-8_5
  25. M Saifee, N Inamda, D Dhamecha, A Rathi. Drug polymorphism: a review. International Journal of Health Research. 2010;2(4). doi:10.4314/ijhr.v2i4.55423 read 9 October 2026. doi.org/10.4314/ijhr.v2i4.55423
  26. Lu J, Rohani S. Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs). Current Medicinal Chemistry. :884-905. doi:10.2174/092986709787549299 read 9 October 2026. doi.org/10.2174/092986709787549299

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). Drug Excipients: Definition, Functional Categories and the Limits of the Term “Inactive”. Pubrica. https://pubrica.com/academy/concepts-definitions/what-is-drug-excipient/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Excipient reporting block for the methods section

One row per component, to be completed before the formulation paragraph is written. Rows that cannot be completed identify the questions a reviewer is likely to ask. Quantities are given twice deliberately: per unit for the product, percentage w/w for transfer to another batch size.

EXCIPIENT REPORTING BLOCK
Product / formulation code: ______________   Dosage form: ______________
Route of administration: ______________   Batch size: ______________

For EACH component, including the active substance:

  Component ................ ______________________________________
  Role ..................... [ ] active  [ ] diluent  [ ] binder
                             [ ] disintegrant  [ ] lubricant / glidant
                             [ ] surfactant / solubiliser  [ ] stabiliser
                             [ ] preservative  [ ] coating / colour / flavour
                             [ ] processing aid (removed; state residual limit)
  Grade / trade designation  ______________________________________
      (viscosity grade, substitution type, particle-size grade as applicable)
  Specification met ........ [ ] USP-NF monograph, current revision
                             [ ] Ph. Eur. / JP monograph
                             [ ] in-house specification (attach)
      Functionality-related characteristics tested? ______________
  Supplier ................. ______________   Lot: ______________
  Amount per unit .......... __________ mg
  Amount as % w/w .......... __________ %
  Precedent for this level . [ ] FDA IID: route ____________ dosage form ____________
                                  max potency ____________ retrieved ____ / ____ / ______
                             [ ] prior marketed product (name) ______________
                             [ ] own toxicology data (cite)

POPULATION CHECK  (complete if neonates, children, pregnancy or frail older adults
                   are in the intended population)
  [ ] Ethanol content per dose stated ................ __________
  [ ] Benzyl alcohol content per dose stated ......... __________
  [ ] Propylene glycol content per dose stated ....... __________
  [ ] Preservative, colourant and sweetener content stated
  [ ] Exposure per kg body weight per day calculated for the smallest
      intended patient .................................. __________

COMPATIBILITY AND STABILITY
  [ ] Binary drug-excipient mixtures tested; conditions: ______________
  [ ] Analytical method named, with LOD / LOQ: ______________
  [ ] New degradation products: none / listed: ______________
  [ ] Solid-form change checked (XRPD / DSC) after storage
  [ ] Pairs NOT tested, and why: ______________________________________

WHAT THE PARAGRAPH MUST SAY (self-check)
  [ ] Every component has identity, grade, function, quantity and specification
  [ ] No component is described only as "pharmaceutical grade"
  [ ] Supplier and lot given for anything whose functionality drives the result
  [ ] The design trade-off accepted (e.g. strength vs disintegration) is stated
  [ ] Container closure components described separately from excipients

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s medical writing and regulatory writing teams build formulation and materials sections from the batch record rather than from the draft, so that every component carries grade, function, quantity, source and specification before a reviewer asks. Pubrica also checks excipient levels against the Inactive Ingredient Database on the matching route and dosage form, and flags where a level, a population or a novel co-processed grade will need its own justification.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Pubrica reviews formulation sections and batch records and identifies the components that a reviewer would be unable to reproduce.

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.